TuHURA Biosciences (HURA) Stock Price, News & Analysis

Company Overview

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Key Stats

• Today's Range: $3.30 to $3.46
• 50-Day Range: N/A
• 52-Week Range: $2.84 to $17.36
• Volume: 5,926 shs
• Average Volume: 263,865 shs
• Market Capitalization: $5.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

TuHURA Biosciences Stock Analysis - MarketRank™

TuHURA Biosciences scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

TuHURA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TuHURA Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

TuHURA Biosciences has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HURA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TuHURA Biosciences does not currently pay a dividend.

Dividend Growth

TuHURA Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for HURA.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

TuHURA Biosciences has a news sentiment score of -3.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for TuHURA Biosciences this week, compared to 0 articles on an average week.

Search Interest

5 people have searched for HURA on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added TuHURA Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TuHURA Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.20% of the stock of TuHURA Biosciences is held by insiders.

Percentage Held by Institutions

Only 0.62% of the stock of TuHURA Biosciences is held by institutions.

HURA Stock Analysis - Frequently Asked Questions

How have HURA shares performed this year?

TuHURA Biosciences' stock was trading at $4.98 at the start of the year. Since then, HURA stock has decreased by 38.2% and is now trading at $3.08.
View the best growth stocks for 2024 here.

How do I buy shares of TuHURA Biosciences?

Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HURA
• CUSIP: N/A
• CIK: 1498382
• Web: N/A
• Phone: (813) 875-6600
• Fax: 604-608-5685
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $15.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +355.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,320,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -152.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.54
• Quick Ratio: 1.54

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.11) per share
• Price / Book: -0.80

Miscellaneous

• Outstanding Shares: 1,590,000
• Free Float: 1,589,000
• Market Cap: $5.23 million
• Optionable: N/A
• Beta: 0.82